• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Characterization of the organ-specific subsets of MDSCs and its application to novel treatment using arthritis model mice

Research Project

Project/Area Number 18K16148
Research Category

Grant-in-Aid for Early-Career Scientists

Allocation TypeMulti-year Fund
Review Section Basic Section 54020:Connective tissue disease and allergy-related
Research InstitutionKobe University

Principal Investigator

Sendo Sho  神戸大学, 医学部附属病院, 特定助教 (40813415)

Project Period (FY) 2021-11-01 – 2025-03-31
Project Status Completed (Fiscal Year 2024)
Budget Amount *help
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
KeywordsMDSC / 関節リウマチモデルマウス / 間質性肺炎 / 組織特異性 / 組織特異的 / JAK阻害薬 / SKGマウス / 関節炎 / ケモカインレセプター / 抑制能 / T細胞増殖 / Th17細胞分化
Outline of Research at the Start

骨髄由来抑制細胞(MDSC)は悪性腫瘍や炎症性疾患で骨髄から誘導される抑制能をもった細胞集団であるが、各組織でどのような動態を示すか、表現型や機能からさらに詳細な異なるサブセットに分類できるかは不明である。これまでの研究で、関節由来MDSCは脾臓由来MDSCとも骨髄由来MDSCとも異なる性質を持つことを明らかにした。また、JAK阻害剤がSTATのリン酸化を抑制し炎症肺のMDSCを増加させることなどを明らかにした。これらの結果は、炎症組織由来MDSCはリンパ組織由来MDSCと異なった性質を持ち、ある種の薬剤はMDSCの増殖や機能を制御することが示唆され、MDSCを介した治療への応用が期待される。

Outline of Final Research Achievements

This study investigated whether the properties of MDSCs (myeloid-derived suppressor cells), which suppress immune responses, differ depending on their tissue of origin. It was revealed that MDSCs isolated from inflamed joints of mice possess the ability to differentiate into osteoclasts, the cells responsible for bone resorption. In addition, MDSCs isolated from inflamed lungs were found to produce high levels of chemokines, which attract other immune cells. Administration of an inhibitor targeting the corresponding chemokine receptors led to improvement of lung pathology in a mouse model of interstitial lung disease. Furthermore, it was demonstrated that JAK inhibitors used in the treatment of rheumatoid arthritis induce MDSC expansion, and that this effect varies depending on the type of JAK inhibitor.

Academic Significance and Societal Importance of the Research Achievements

本研究では、MDSCの臓器由来による機能の違いを明らかにした。炎症関節由来MDSCは破骨細胞への分化能を、炎症肺由来MDSCはケモカインの高産生能を示し、それぞれ病態形成に関与していることが示唆された。加えて、関節リウマチ治療に用いられるJAK阻害薬がMDSCの増加を誘導し、その効果に薬剤ごとの差異があることを見出した。これらの成果は、自己免疫疾患における免疫調節機構の理解を深めるとともに、MDSCやケモカイン経路を標的とした新規治療法の開発や、JAK阻害薬の個別化治療戦略に貢献する可能性があり、学術的、社会的意義を持つ。

Report

(6 results)
  • 2024 Annual Research Report   Final Research Report ( PDF )
  • 2023 Research-status Report
  • 2022 Research-status Report
  • 2019 Annual Research Report
  • 2018 Research-status Report
  • Research Products

    (11 results)

All 2025 2024 2022 2019 2018

All Journal Article (2 results) (of which Peer Reviewed: 2 results,  Open Access: 2 results) Presentation (9 results) (of which Int'l Joint Research: 3 results)

  • [Journal Article] Myeloid-derived suppressor cell-derived osteoclasts with bone resorption capacity in the joints of arthritic SKG mice2024

    • Author(s)
      Fujikawa Yoshikazu、Sendo Sho、del Peral Fanjul Alfonso、Yamada Hirotaka、Uto Kenichi、Yamamoto Yuzuru、Nagamoto Takumi、Morinobu Akio、Saegusa Jun
    • Journal Title

      Frontiers in Immunology

      Volume: 15 Pages: 1168323-1168323

    • DOI

      10.3389/fimmu.2024.1168323

    • Related Report
      2023 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice.2019

    • Author(s)
      Sendo S, Saegusa J, Yamada H, Nishimura K, Morinobu A.
    • Journal Title

      Arthritis Research Therapy

      Volume: 6 Issue: 1 Pages: 184-184

    • DOI

      10.1186/s13075-019-1963-2

    • NAID

      120006713587

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access
  • [Presentation] The CXCL9, CXCL10, CXCL11 /CXCR3 Axis, a major role player in the pathophysiology of Interstitial Lung Disease in SKG mice2025

    • Author(s)
      Alfonso Del Peral Fanjul, Sho Sendo, Mai Yamashita, Shinya Ichikawa, Hirotaka Yamada, Takaichi Okano, Keisuke Nishimura, Yo Ueda, Jun Saegusa
    • Organizer
      第69回日本リウマチ学会総会・学術集会
    • Related Report
      2024 Annual Research Report
  • [Presentation] Myeloid-derived suppressor cells from the inflamed joints of arthritic SKG mice differentiate into osteoclasts and exacerbate arthritis2024

    • Author(s)
      Alfonso del Peral Fanjul, Sho Sendo, Yoshikazu Fujikawa, Takumi Nagamoto, Hirotaka Yamada, Akio Morinobu, Jun Saegusa
    • Organizer
      第52回日本免疫学会学術集会
    • Related Report
      2023 Research-status Report
  • [Presentation] Characterization of Myeloid-Derived Suppressor Cells in Inflammatory Joint of SKG Mice2022

    • Author(s)
      Yoshikazu Fujikawa, Sho Sendo, Yoko Nose, Shinya Ichikawa, Katsuhiko Yoneda, Takumi Nagamoto, Yuzuru Yamamoto, Yoshihide Ichise, Hirotaka Yamada, Takaichi Okano, Keisuke Nishimura, Yo Ueda and Jun Saegusa
    • Organizer
      第66回日本リウマチ学会総会・学術集会抄録集
    • Related Report
      2022 Research-status Report
  • [Presentation] MDSCS IN THE INFLAMMATORY JOINT OF SKG MICE HAVE BOTH T CELL SUPPRESSIVE ABILITY AND OSTEOCLAST DIFFERENTIATION POTENTIAL2022

    • Author(s)
      Y. Fujikawa, S. Sendo, T. Nagamoto, Y. Yamamoto, H. Yamada, T. Okano, K. Nishimura, Y. Ueda`, J. Saegusa
    • Organizer
      EULAR2022-Anuual European Congress of Rheumatology
    • Related Report
      2022 Research-status Report
    • Int'l Joint Research
  • [Presentation] MDSCs in Inflammatory Joints of SKG Mice Suppress T Cells and Differentiate into Osteoclasts2022

    • Author(s)
      Yoshikazu Fujikawa, Sho Sendo, Takumi Nagamoto, Yuzuru Yamamoto, Takaichi Okano, Keisuke Nishimura, Yo Ueda and Jun Saegusa
    • Organizer
      ACR/ARHP Annual Meeting 2022
    • Related Report
      2022 Research-status Report
    • Int'l Joint Research
  • [Presentation] Tofacitinib Facilitate the Expansion of MDSCs and Suppress the Progression of Interstitial Lung Disease in SKG Mice2018

    • Author(s)
      Sho Sendo*, Jun Saegusa, Yo Ueda, Ikuko Naka, Yoshihide Ichise, Hirotaka Yamada, Yuzuru Yamamoto, Akio Morinobu
    • Organizer
      第62回日本リウマチ学会総会・学術集会
    • Related Report
      2018 Research-status Report
  • [Presentation] Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice2018

    • Author(s)
      Sho Sendo, Jun Saegusa, Yoshihide Ichise, Hirotaka Yamada, Ikuko Naka, Yo Ueda, Takaichi Okano, Akio Morinobu
    • Organizer
      American College of Rheumatology 82nd Annual Scientific Meeting
    • Related Report
      2018 Research-status Report
    • Int'l Joint Research
  • [Presentation] トファシチニブは骨髄由来抑制性細胞(MDSC)の増殖を促しSKGマウスの間質性肺炎を抑制する2018

    • Author(s)
      千藤 荘*, 三枝 淳, 山田 啓貴, 上田 洋, 森信 暁雄
    • Organizer
      第46回 日本臨床免疫学会総会
    • Related Report
      2018 Research-status Report
  • [Presentation] Tofacitinib Facilitates the Expansion of Myeloid-Derived Suppressor Cells and Ameliorates Interstitial Lund Disease in SKG Mice2018

    • Author(s)
      Sho Sendo*, Jun Saegusa, Hirotaka Yamada, Akio Morinobu
    • Organizer
      第47回日本免疫学会総会・学術集会
    • Related Report
      2018 Research-status Report

URL: 

Published: 2018-04-23   Modified: 2026-01-16  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi